Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis

2001 ◽  
Vol 1 (3) ◽  
pp. 201-208
Author(s):  
Moiz Bakhiet
Keyword(s):  
Multiple Sclerosis ◽  
Therapeutic Agents ◽  
Novel Therapeutic

scholarly journals Scoring disease in an animal model of multiple sclerosis using a novel infrared-based automated activity-monitoring system

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Shailesh K. Shahi ◽  
Samantha N. Freedman ◽  
Rachel A. Dahl ◽  
Nitin J. Karandikar ◽  
Ashutosh K. Mangalam
Keyword(s):  
Multiple Sclerosis ◽  
Animal Model ◽  
Disease Severity ◽  
Inverse Correlation ◽  
Therapeutic Agents ◽  
Scoring Methods ◽  
Automated Method ◽  
The Central Nervous System ◽  
Disease Scoring ◽  
Novel Therapeutic

AbstractMultiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CNS). Its corresponding animal model, experimental autoimmune encephalomyelitis (EAE), is widely used to understand disease pathogenesis and test novel therapeutic agents. However, existing methods to score EAE disease severity are subjective and often vary between individual researchers, making it difficult to translate findings across different studies. An enhanced automated method of disease scoring would eliminate subjectivity and reduce operator-dependent errors. Here, we used an Infra-Red Activity Monitoring System (IRAMS) to measure murine locomotor activity as a surrogate measure of disease severity and compared it to standard EAE scoring methods. In mice immunized with CNS-specific myelin antigens, we observed an inverse correlation between disease severity and mouse activity, with the IRAMS showing enhanced disease scoring compared to standard EAE scoring methods. Relative to standard EAE scoring methods, IRAMS showed comparable measurement of disease relapses and remissions in the SJL/J-relapsing-remitting model of EAE, and could comparably assess the therapeutic efficiency of the MS drug, Copaxone (Glatiramer acetate-GA). Thus, the IRAMS is a method to measure disease severity in EAE without subjective bias and is a tool to consistently assess the efficacy of novel therapeutic agents for MS.

ChemInform Abstract: Synthesis of Novel Therapeutic Agents for the Treatment of Multiple Sclerosis: A Brief Overview

ChemInform ◽  
2013 ◽  
Vol 44 (23) ◽  
pp. no-no
Author(s):  
Naveen Mulakayala ◽  
Pallavi Rao ◽  
Javed Iqbal ◽  
Rakeshwar Bandichhor ◽  
Srinivas Oruganti
Keyword(s):  
Multiple Sclerosis ◽  
Therapeutic Agents ◽  
Novel Therapeutic

Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview

2013 ◽  
Vol 60 ◽  
pp. 170-186 ◽  
Author(s):  
Naveen Mulakayala ◽  
Pallavi Rao ◽  
Javed Iqbal ◽  
Rakeshwar Bandichhor ◽  
Srinivas Oruganti
Keyword(s):  
Multiple Sclerosis ◽  
Therapeutic Agents ◽  
Novel Therapeutic

scholarly journals Chalepin and Chalepensin: Occurrence, Biosynthesis and Therapeutic Potential

Molecules ◽  
2021 ◽  
Vol 26 (6) ◽  
pp. 1609
Author(s):  
Lutfun Nahar ◽  
Shaymaa Al-Majmaie ◽  
Afaf Al-Groshi ◽  
Azhar Rasul ◽  
Satyajit D. Sarker
Keyword(s):  
Medicinal Plant ◽  
Critical Appraisal ◽  
Therapeutic Potential ◽  
Therapeutic Agents ◽  
Review Article ◽  
Natural Distribution ◽  
Antiplatelet Aggregation ◽  
Ruta Chalepensis ◽  
The Family ◽  
Novel Therapeutic

Dihydrofuranocoumarin, chalepin (1) and furanocoumarin, chalepensin (2) are 3-prenylated bioactive coumarins, first isolated from the well-known medicinal plant Ruta chalepensis L. (Fam: Rutaceae) but also distributed in various species of the genera Boenminghausenia, Clausena and Ruta. The distribution of these compounds appears to be restricted to the plants of the family Rutaceae. To date, there have been a considerable number of bioactivity studies performed on coumarins 1 and 2, which include their anticancer, antidiabetic, antifertility, antimicrobial, antiplatelet aggregation, antiprotozoal, antiviral and calcium antagonistic properties. This review article presents a critical appraisal of publications on bioactivity of these 3-prenylated coumarins in the light of their feasibility as novel therapeutic agents and investigate their natural distribution in the plant kingdom, as well as a plausible biosynthetic route.

scholarly journals Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1781
Author(s):  
Gustavo A. Arias-Pinilla ◽  
Helmout Modjtahedi
Keyword(s):  
Pancreatic Cancer ◽  
Monoclonal Antibodies ◽  
Antibody Therapy ◽  
Therapeutic Targets ◽  
Poor Response ◽  
Therapeutic Agents ◽  
Therapeutic Interventions ◽  
Western World ◽  
Wide Range ◽  
Novel Therapeutic

Pancreatic cancer remains as one of the most aggressive cancer types. In the absence of reliable biomarkers for its early detection and more effective therapeutic interventions, pancreatic cancer is projected to become the second leading cause of cancer death in the Western world in the next decade. Therefore, it is essential to discover novel therapeutic targets and to develop more effective and pancreatic cancer-specific therapeutic agents. To date, 45 monoclonal antibodies (mAbs) have been approved for the treatment of patients with a wide range of cancers; however, none has yet been approved for pancreatic cancer. In this comprehensive review, we discuss the FDA approved anticancer mAb-based drugs, the results of preclinical studies and clinical trials with mAbs in pancreatic cancer and the factors contributing to the poor response to antibody therapy (e.g. tumour heterogeneity, desmoplastic stroma). MAb technology is an excellent tool for studying the complex biology of pancreatic cancer, to discover novel therapeutic targets and to develop various forms of antibody-based therapeutic agents and companion diagnostic tests for the selection of patients who are more likely to benefit from such therapy. These should result in the approval and routine use of antibody-based agents for the treatment of pancreatic cancer patients in the future.

Sign in / Sign up

Export Citation Format

Share Document